CIN : L22193DL2024PLC428183
ANONDITA MEDICARE LIMITED
AN ISO 9001:2015 ISO 13485:2016 & CDSCO CERTIFIED CO.
Manufacturer of Condoms

November 16, 2026

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Subject: Submission of Investor Presentation for H1 FY2027

Ref.: SEBI Circular: HO/49/14/14(7)2025CFD-POD2/I/3762/2026 dated 30th January 2026

SYMBOL: ANONDITA
ISIN: INE0VTV01012

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose the Investor Presentation pertaining to the financial results for H1 FY2027.

Further, a copy of the said Investor Presentation is also enclosed as Annexure A

The said presentation will also uploaded on the website of the Company: https://anonditamedicare.com/.

Kindly take the above information on your record.

Thanking You.
Yours faithfully,

For and on behalf of
ANONDITA MEDICARE LIMITED

BHAWNA BISHT
Digitally signed by BHAWNA BISHT
Date: 2026.11.16 14:32:42 +05'30'

Bhawna Bisht
Company Secretary and Compliance Officer
M No : A70843



Regd. Off.:Flat No. 704, Narmada Block N-6, Sector - D, Block - C, Vasant Kunj, New Delhi -110070
Corp Off. : D-001, Sector-80, Noida-201305, (U.P.) INDIA
Tel.: 0120-4520300/1/2/3 till 99 (100 Lines) Fax : 0120-4520314
E- mail : info@anonditamedicare.com I accounts@anonditahealthcare.com
Website: www.anonditamedicare.com

Anondita Medicare Limited

(Formerly known as Anondita Healthcare)

Investor Presentation



Safe Harbour Statement

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

This presentation and its accompanying materials (collectively, the "Presentation") have been prepared by Anondita Medicare Limited ("Anondita," "the Company," or "we") for informational and discussion purposes only. This Presentation does not constitute an offer to sell or solicitation of an offer to purchase any securities, investment advice, or recommendation, nor should it be relied upon as the basis for any investment decision or contractual commitment. Any securities offering by the Company will be made exclusively through formal offering documents containing complete information about the Company, its business, and associated risks.

While the information contained herein has been compiled from sources the Company believes to be reliable, the Company makes no representations or warranties, express or implied, regarding the accuracy, completeness, or fairness of the information presented. This Presentation may not include all material information concerning the Company, and any reliance on this information is entirely at the recipient's own risk. The Company expressly disclaims all liability for any errors, omissions, or inaccuracies contained herein.

This Presentation contains forward-looking statements concerning the Company's business prospects, market opportunities, and strategic outlook based on current expectations and assumptions. These statements are subject to significant risks and uncertainties, and actual results may differ materially from those expressed or implied. Various factors may cause actual outcomes to vary, including economic conditions in India and internationally, industry trends and competitive dynamics, execution of business strategies, technological developments, revenue variability, market acceptance, regulatory changes, and other business risks. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Any forward-looking statements, projections, or opinions attributed to third parties included in this Presentation are not endorsed by the Company, and the Company assumes no responsibility for their accuracy or reliability. By reviewing this Presentation, recipients acknowledge that they have read, understood, and agree to be bound by the terms of this disclaimer.

About Anondita Medicare Limited

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Anondita Medicare Limited, is an Indian manufacturer of **male and female condoms**, operating under its flagship brand **"COBRA."** The company runs its own manufacturing facility and follows a quality-driven, compliant production model.

The company is led by **Mr. Anupam Ghosh, Managing Director and Promoter**, who brings over **25 years of experience** in the healthcare and contraceptive products industry. His deep domain expertise, entrepreneurial background, and execution capability provide strong leadership and strategic direction to the company.

With a strong domestic presence, particularly in **North India**, Anondita Medicare is actively **expanding its geographical footprint** across India and international markets. Ongoing initiatives such as **UN qualification, automation-led capacity enhancement**, and **patented female condom products** position the company for scalable growth and long-term value creation.

The company has expanded from its existing **D1 facility** by acquiring adjacent units for **D2 and D3 expansion**, enhancing production capacity, operational efficiency, and future scalability.



Management Overview



Mr. Anupam Ghosh

Managing Director & Promoter

Role & Experience

- Over 25 years of experience in the healthcare products industry.
- Expertise in leadership and strategic business growth.



Mr. Reshant Ghosh

Whole -Time Director & Promoter

Role & Experience

- Founder and Director of Anondita Pharma and Latex Limited (Formerly Known as M/s Anondita Healthcare and Rubber Products India Limited
- Expertise in marketing and business development.



Mr. Lakhinder Singh

IRS Retired
Director

Role & Experience

- Over 36 years of experience in public service.
- Served as Chief Commissioner, Customs & Central Excise, Meerut & Lucknow.

Mission & Vision

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

MISSION ROADMAP

2026
Addition of manufacturing facilities for female latex condoms.

2027
Commencement of female latex condom manufacturing.

2028
Aggressive brand building and market expansion across India and international markets.

2029
Latex plantation ready for commercial operations, strengthening backward integration; additionally, commence Surgical Gloves Manufacturing.

2030
Establish India's first manufacturing setup for Personal Care Massage Products, marking expansion into the personal care segment.

VISION

Anondita Medicare Ltd. aspires to be a leading force in the fight against HIV/AIDS and the prevention of unintended pregnancies by delivering safe, reliable, and high-quality sexual health and personal wellness products. With a strong focus on innovation and excellence, the Company aims to broaden its product portfolio, expand its footprint in domestic and global markets, and establish itself as a trusted name in global healthcare.
We are the only manufacturers in India who are producing male & female latex & non latex condoms.





Key Facts & Figures

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

30+
Years of Experience

15
Manufacturing lines
(**869 Million** Installed Capacity)

FY26 (In ₹ Lakhs)
Revenue – 13,741.57
EBITDA – 5,150.85
Net Profit – 3,429.65

H1 FY27 (In ₹ Lakhs)
Revenue – 7,354.17
EBITDA – 3,329.80
Net Profit – 2,200.60

480+
Team Size

4
Manufacturing lines
Under Trial
(**250 Million** Installed Capacity)

4
Manufacturing lines
Under WIP



Quality Assurance

- Stringent quality control processes
- Each and Every Condom is Electronically Tested
- ISO Certification (ISO - 9001; ISO 13485:2016)
- Bureau of Indian Standards (BIS) 0f Company has been nominated for MSME Award 5000.
- Certificate of Good Manufacturing Practices (GMP)
- Medical Device License (MD License)
- WHO certification

Key Events And Milestones

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

1999

- The erstwhile proprietorship “M/s Health Care Products” was started by our current promoter,
- Mr. Anupam Ghosh for the packaging and sale of contraceptives and gloves.

2001-2010

- Started Marketing and Packaging in our brand by Purchasing condoms from TTK & JK.
- Established our own manufacturing Unit in Noida.
- Started our manufacturing by providing services to Mankind Pharma Ltd. For "ManForce" brand.
- Started supply of our product to ZVDUS.

2011-2015

- Got our factory approved by KFW Germany and got the India's first manufacturing unit order to supply to Government of Nepal.
- The proprietorship was renamed to “M/s Anondita Healthcare” in 2013
- Established a new state of art Unit In Noida with additional manufacturing facility.

2016-2018

- Got our 1st order from Government to supply NIRODH.
- We got certification from WHO GMP from Drug licensing and Controlling authority, Govt. of India.
- Got Business Awards for ANONDITA HEALTHCARE AS EMERGING HEALTHCARE COMPANY OF THE YEAR in the second edition of the Times Business Awards 2019, held at Roseate House, Aerocity, New Delhi.

2019

- Got mentioned In various articles in newspapers, newsletters, etc., and awards as a leading manufacturer of condoms and surgical gloves.
- Recognized by various articles in newspapers, newsletters, etc., on CSR Initiatives for welfare activities by the Anondita Healthcare.

2024

- Incorporation of our Company, Anondita Medicare Limited.
- Takeover of M/s Anondita Healthcare by our company vide Business Takeover Agreement dated April 01, 2024
- Our company acquired 100% shareholding in “Anondita Healthcare and Rubber Products India Limited” vide a Share Purchase Agreement dated April 01, 2024, entered into between Anondita Pharma and Latex Limited (Formerly Known as M/s Anondita Healthcare Rubber and Products India Limited) (First Party), Mr. Reshant Ghosh and Ms. Sonia Ghosh (Second Party) and our Company (Third Party).

2025

- Successfully Listed on the NSE
- Completed South Africa Audit
- Expanded Export Presence across Brazil, South Africa, Uzbekistan, Nepal, Kenya, Cuba & UAE
- Received MSME Excellence Award
- Achieved Domestic & International MDSAP Certification
- Recognized by the UN of Brazil
- Vendor Registration completed in Brazil & South Africa
- Successfully Completed Female Latex Condom Trials
- Expansion of production capacity by 307 million for male condoms

Expansion of facility by acquiring adjacent with by D2 & D3

Why Invest in Anondita Medicare?

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

India & World's only manufacturer of both male & female latex and non-latex condoms

869 million installed capacity with expansion underway

Patent-backed female condom opportunity

Strong export pipeline (UNFPA, South Africa, Brazil)

Asset-light scalable manufacturing with improving margins

Significant operating leverage driving future earnings growth



Anondita Medicare Limited – Rights Issue Completed

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Scaling Capacity. Expanding Markets. Building the Next Phase of Growth.

₹91.03 Cr Successfully Raised Through Rights Issue | Issue Price: ₹950 per Share

Capital Raised to Accelerate the Company's Next Phase of Growth

- Expansion into female latex and non-latex condom manufacturing
- Strengthening manufacturing infrastructure and production capabilities
- Funding incremental working capital requirements as business scales
- Supporting expansion across domestic and international markets
- Enabling the Company to capitalize on its growing institutional and export opportunity



1

Female Condom Opportunity

The Company is expanding manufacturing capabilities for female latex and non-latex condoms, a relatively underpenetrated category with significant institutional and global procurement potential.
The presentation estimates the global female condom market at 700 Mn–1.5 Bn pieces annually for commercial/public procurement demand, against potential demand of 2–5 Bn pieces annually.

2

Large Institutional Procurement Opportunity

Global institutional procurement represents a significant volume market:

- **UNFPA:** ~680 Mn+ male condoms + ~6 Mn female condoms annually
- **Global Fund & Government Programmes:** Hundreds of millions of condoms procured annually
- **NGOs & Social Marketing Organisations:** ~800–900 Mn condoms distributed annually
- **Total Institutional Distribution:** ~1.5–2.0 Bn condoms annually

3

Capacity Already Being Scaled

The Company added approximately **307 Mn pieces of male condom capacity in February 2026**, taking its installed capacity to approximately **869 Mn pieces per annum**.
The newly added capacity provides an opportunity for further utilisation-led growth as market demand and customer orders increase.

₹91.03 Cr Capital Raise → Capacity Creation → Scale-up → Market Expansion

Manufacturing Facility

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Enabling operational scale-up and future growth

Noida, Uttar Pradesh
Location


~9,290 Sq. Mt.
Total built-up area

5,62 Million pieces
Annual production capacity

15
Operational Manufacturing lines

869 Million pieces
Annual Production
(307 million newly added on Feb 23, 2026).

15 manufacturing lines operational
4 lines under trial
4 lines under WIP



* The additional capacity of 307 million was added towards on Feb'26, at the utilization of 8-10%

Expanding into Nepal, Bhutan & Bangladesh

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

NEPAL

3 distribution partners | Appointed Oct 2026

Lotus Pharmaceuticals Ltd.
Kathmandu | Pharma & FMCG distributor
Condoms & personal lubricants; to explore Daraz e-commerce

SSR Traders
Central Kathmandu | Distributor
Sales commenced: 3-piece & 10-piece condom packs

Hitayu Holdings Pvt. Ltd.
Chhetrapati, Kathmandu | Medical products importer
Surgical gloves, contraceptives, nebulisers, pregnancy test kits & lubricants

BHUTAN

1 distribution partner | Arrangement finalised

Prema Olo Pharmaceuticals & Medical Supply
Importer & distributor | Government supply focus

Products
Condoms & surgical gloves

Key channels
Government hospitals & clinics – route into institutional healthcare supply (subject to applicable requirements)

BANGLADESH

2 distribution partners | COBRA condoms

National Marketing Company
Jessore | Medical products importer
Premium condoms & surgical gloves – northern Bangladesh

R K Corporation
Nawabganj, Dhaka | Pharma & equipment importer
Economy range (Midnight, COBRA CC) – interior markets of eastern Bangladesh

Portfolio
COBRA condoms across premium and economy segments

First sales live in Nepal; COBRA now expanding across 3 markets.

Future Product Expansion & Innovation Strategy

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Anondita Medicare Limited is committed to strengthening its presence in the healthcare and in sexual wellness products category through continuous innovation, product diversification, and expansion into new healthcare categories.

Following the successful launch of the Cobra Shubh Samachar Pregnancy Test Kit, the Company plans to further expand its product portfolio with multiple consumer healthcare and wellness products under the “COBRA” brand.

Proposed Product Expansion Pipeline



Cobra Premium Body Deodorant Range



Cobra Smooth Lubricating Gel



Cobra Shubh Samachar Pregnancy Test Kit



Gyno gloves



Safe hands household Gloves



Anti microbial gloves

OUR STRATEGIC FOCUS

- Strengthening brand presence in domestic and international markets
- Expanding healthcare product offerings
- Enhancing customer reach through innovation-driven solutions
- Building a diversified and sustainable business model

Our Commitment

- Focus on Research & Innovation
- Ensuring Quality & Safety
- Enhancing Consumer Well-being
- Building Trust & Long-term Relationships
- Driving Growth with Sustainable Solutions

Global Certifications Enabling Export Growth

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

MDSAP Certification (ISO 13485:2016)



CERTIFICATE

dqs

This is to certify that the company

Anondita Medicare Limited

D-001, Sector 80, Noida
Gautam Buddha Nagar
Uttar Pradesh – 201305
India

with the organizational units/sites as listed in the annex

has implemented and maintains a **Quality Management System**.

Scope of certification:
Design, Development, Manufacturing and Distribution of Male and Female Condoms.
- BRA

Through an audit, documented in a report, performed by DQS Medizinprodukte GmbH, it was verified that the management system fulfills the requirements of the following standard:

ISO 13485 : 2016

including applicable country-specific regulatory requirements, as indicated below the scope (full references of abbreviations are listed in the annex)

Certificate registration no.	31633484 MDSAP16
Certificate unique ID	1000263822
Effective date	2025-11-25
Expiry date	2028-11-24
Frankfurt am Main	2025-11-25

MDSAP
Medical Device Single Audit Program

DQS Medizinprodukte GmbH

Heinrich von Mettenheim
Managing Director

August-Schanz-Straße 21, 60433 Frankfurt am Main,
Tel. +49 (0) 69 95427-300, info-med@dqs.de
DQS Medizinprodukte GmbH is recognized under the Medical Devices Single Audit Program.
The validity of the certification can only be verified by the QR-code.

1 / 3

- Covers **Male & Female Condoms**
- Accepted across **Australia, Brazil, Canada, Japan & USA**
- Strengthens regulatory compliance and quality systems
- Enables entry into highly regulated medical device markets
- Supports global expansion and export-led growth

India's First Company to receive **MDSAP Certification for male & female condoms.**

SABS Certification (South Africa)



SABS

Permit to Apply Certification Mark

ANONDITA MEDICARE LIMITED
Co Reg. L22193DL2024PLC428183
UTTAR PRADESH, INDIA

to apply the certification mark

SABS APPROVED

in respect of the mark specification

SANS 4074:2017
TO: NATURAL RUBBER LATEX MALE CONDOMS - REQUIREMENTS AND TEST METHODS


Permit Number	12044/18828
Effective Date	07 January 2026
Expiry Date	04 August 2028
Date of Original Registration	05 August 2025
Chief Executive Officer	

sanas

- Certified for Natural Rubber Latex Male Condoms
- Compliant with **SANS 4074:2017**
- Applicable to select **COBRA** variants
- Enables access to South Africa and African export markets
- Strengthens credibility with government bodies, NGOs & institutional buyers

Supports expansion into **regulated African markets** and reinforces compliance-driven manufacturing.

Global Condom Market Outlook



Regional Market Overview

1. **Asia Pacific (incl. SE Asia): ~45–50% of global demand** – largest & fastest-growing region driven by population scale, government programs, and rising retail penetration.
2. **North America (US): High-value commercial market** with premium pricing; retail-led demand and strong growth in non-latex and online sales.
3. **Europe: Mature, stable market** with high awareness and consistent replacement demand through pharmacies and modern trade.
4. **Latin America: Mid-growth region** led by Brazil & Mexico; mix of commercial sales and government/NGO programs.
5. **Africa: Low retail value, very high unit volumes;** demand largely fulfilled via donor-funded public health distribution.

Global Procurement & Donor Market (Volumes)

UNFPA:
~680+ million male condoms + ~6 million female condoms annually across Africa, Asia & LATAM.


Total global institutional distribution:
~1.5–2.0 billion condoms per year, providing strong volume visibility.


Global Fund & Government Programs:
Hundreds of millions of condoms procured every year for HIV/STI prevention in high-burden regions.

NGOs & Social Marketing Organizations:
~800–900 million condoms distributed annually across 100+ countries.

Indian Condom Market Outlook

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)





Based on Product Type:

- Male condoms dominate the Indian market with **over 95% share**, driven by significantly higher adoption than female condoms.
- Only **~8% of women** use condoms as a contraceptive method in India. Male condoms are also far more affordable, costing **~USD 0.12 per unit**, compared to **~USD 2.5 per unit** for female condoms.

By Material Type: Non-Latex Innovation Drives Premium Growth


- Latex products accounted for 80.45% of 2024 revenue due to their cost advantages. While latex maintains a substantial market share, non-latex alternatives are expected to grow at a 10.56% CAGR, driven by consumer demand for allergy-free products and enhanced sensation.

Source : Condom Market, marknteladvisors, mordorintelligence

India Condom Market Share

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

MARKET SIZE (INDIA) FY26 (EST.) : INR 2,600 – 2,800 CRORE



Others Include
(Key Players)

- Anondita Medicare Ltd
- Pakka Limited
- Parag Rubber Industries
- Super Star Rubber Industries
- Global Protection Corp Ltd
- Hindustan Latex Family Planning
- JMS Rubber Co.
- Premier Rubber Industries
- Other Regional & Private Labels

Global Female Condom Market

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Global Female Condom Market Size



2–5 Billion

Pieces Annually (Potential Demand)

700 Million To 1.5 Billion

Pieces Annually (Commercial/Public Procurement Demand)

USD 350 Million – USD 800 Million

Annually Market Size

Estimated Global Market Share

Company	Market Share
Veru Inc. (FC2)	55%–70%
Cupid Limited	20%–30%
HLL Lifecare Limited	3%–8%
Shanghai Dahua Medical Apparatus Company	2%–5%
Other regional manufacturers	5%–10%

Key Industry Insight

- Global female condom market is growing
- Market remains smaller than male condom market
- Demand depends on donor funding and government procurement cycles

Anondita Medicare: Leading Condom Manufacturer

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Total Production Capacity

1,119 Million
Male Condoms
(250 WIP)

241 Million
Female Condoms
(WIP)

TOTAL
1360 Million
CONDOMS CAPACITY

Total Projected Revenue



1000+
CRORE
Above

Our Commitment

- High manufacturing capacity
- Global quality standards
- Focus on safety, reliability and accessibility
- Driving empowerment through protection

Delivering Protection, Empowering Women, Building a Healthier Future.

Future Market Potential & Global Growth

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

African Healthcare Expansion
Expanding presence across African healthcare and institutional procurement markets.

Building the COBRA Brand
Strengthening COBRA as a premium domestic healthcare & wellness brand

Uzbekistan Market Opportunity
Exploring export opportunities across emerging healthcare markets including Uzbekistan, Nepal, Kenya, Cuba, and UAE.



Domestic Government Procurement
Strong presence in institutional healthcare procurement programs including NACO, Nirodh & Government healthcare agencies

Brazil Market Opportunity
Strategic expansion into Brazil's government healthcare procurement market.

Global Brand Expansion
Expanding COBRA across international healthcare & wellness markets.

Proposed Expansion of Product Porffolio
Addition of gynecological gloves, antimicrobial products and micro-optio medical gloves


Key Strengths


- Quality Assured Manufacturing
- Scalable Production Infrastructure
- Trusted Healthcare Partner
- Sustainable Growth Strategy
- Innovation-Led Expansion


Financial Snapshot (Consolidated)


Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Figures In ₹ Lakhs, Margin In %, EPS in ₹









Income Statement (Consolidated)

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

(Subsidiary, Anondita Pharma and Latex Limited (Formerly Known as M/s Anondita Healthcare and Rubber Products India Limited., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Particulars	H1 FY27	H1 FY26	YOY	FY26	FY25	YOY
Revenue from operations	**7,354.17**	**5,409.70**	**35.94%**	**13,741.57**	**7,699.07**	**78%**
Other Income	60.48	40.78		84.24	13.88	
Total Revenue	**7,414.65**	**5,450.48**	**36.04%**	**13,825.81**	**7,712.95**	**79%**
Cost of materials Consumed	2,775.47	2,353.22		5221.13	3,376.69	
Purchase of Stock - In- Trade	1,295.26	164.93		1,364.54	744.86	
Change in Inventories	-1,277.67	-79.18		-579.51	-293.2	
Employee benefit expense	461.46	348.1		832.85	686.80	
Other Expenses	830.33	702.49		1,835.95	618.70	
Total	4,084.85	3,489.56		8,674.96	5,133.85	
EBITDA	**3,329.80**	**1,960.92**	**69.81%**	**5,150.85**	**2,579.10**	**100%**
EBITDA Margin (%)	**45.28%**	**36.25%**	**903 BPS**	**37.48%**	**33.50%**	**398 BPS**
Depreciation and amortization expense	142.15	40.87		108.09	75.79	
EBIT	3,187.65	1,920.05		5,042.76	2,503.31	
Financial costs	242.28	182.35		353.80	291.09	
Profit before tax	**2,945.37**	**1,737.70**	**69.50%**	**4688.96**	**2212.22**	
Tax Expense						
Current Tax	699.83	420.42		1,015.29	553.25	
Deferred Tax	44.93	15.49		184.94	8.50	
Current Tax Expense Relating to Prior Years	-	-		**59.08**	**-**	
Net Profit	**2,200.60**	**1,301.79**	**69.04%**	**3,429.65**	**1,650.47**	
Net Profit Margin (%)	29.92%	24.06%	586 BPS	**24.96%**	**21.44%**	**352 BPS**
EPS (Diluted)	11.76	9.08	29.52%	21.30	14.67	**45.19%**

Balance sheet (Consolidated)

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

(Subsidiary, Anondita Pharma and Latex Limited (Formerly Known as M/s Anondita Healthcare and Rubber Products India Limited., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹


Equities and Liabilities	FY26	FY25
Shareholder's Funds		
Share Capital	1808.66	1,329.36
Reserves & Surplus	11,114.92	2,380.36
Minority Interest	203.34	118.16
Total	**13,126.92**	**3,827.88**
Non-Current Liabilities		
Long Term Borrowings	2,387.03	1,190.76
Long Term Provisions	17.80	9.83
Deferred Tax Liability	193.52	8.56
Total Non-Current Liabilities	**2,598.35**	**1,209.15**
Current Liabilities		
Short Term Borrowings	973.12	1,548.34
Trade Payables	802.79	381.53
Other current liabilities	248.79	210.06
Provisions	733.14	512.17
Total Current Liabilities	**2,757.85**	**2,652.10**
Total	**18,483.12**	**7,689.13**


Assets	FY26	FY25
Non-current Assets		
Fixed Assets	3,909.76	1237.04
Goodwill	19.18	19.18
Capital work-in-progress	4,149.50	649.61
Non-current investments	331.4	331.4
Deferred Tax Assets (Net)	0.24	0.22
Long Term Loans & Advances	220.79	37.67
Other Non Current Assets	0.16	0.28
Total Non-current Assets	**8,631.03**	**2,275.40**
Current Assets		
Inventories	2,075.01	1,349.86
Trade Receivables	5185.67	2675.33
Cash & Cash Equivalents	965.19	42.19
Short Term Loans & Advances	1,114.56	950.60
Other Current Assets	511.66	395.00
Total Current Assets	**9,852.09**	**5,413.98**
Total	**18,483.12**	**7,689.38**


Financial Snapshot (Standalone)


Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

Figures In ₹ Lakhs, Margin In %, EPS in ₹









Income Statement (Standalone)

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

(Subsidiary, Anondita Pharma and Latex Limited (Formerly Known as M/s Anondita Healthcare and Rubber Products India Limited., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Particulars	H1 FY27	H1 FY26	YOY	FY26	FY25	YOY
Revenue from operations	**5,786.31**	**4,765.06**	**21.43%**	**11,169.62**	**6,051.52**	**85%**
Other Income	90.21	75.56		175.91	36.38	
Total Revenue	**5,876.52**	**4,840.62**	**21.40%**	**11,345.53**	**6,087.90**	**86%**
Cost of materials Consumed	2,774.37	2,353.22		5,221.13	3,376.69	
Purchase of Stock - In- Trade	-	-				
Change in Inventories	-542.12	-186.94		-343.19	-202.97	
Employee benefit expense	426.87	271.06		662.99	483.66	
Other Expenses	733.15	649.21		1,697.84	605.68	
Total	3,392.27	3,086.55		7,238.77	4,263.06	
EBITDA	**2,484.25**	**1,754.07**	**41.63%**	**4,106.76**	**1,824.84**	**125%**
EBITDA Margin (%)	**42.93%**	**36.81%**	**612 BPS**	**36.77%**	**30.16%**	**661 BPS**
Depreciation and amortization expense	141.79	40.03		107.12	74.65	
EBIT	2,342.46	1,714.04		3,999.64	1,750.19	
Financial costs	231.37	181.32		348.27	289.45	
Profit before tax	**2,111.09**	**1,532.71**	**37.74%**	3,651.37	1,460.74	
Tax Expense						
Current Tax	486.9	370.65		745.77	361.15	
Deferred Tax	44.94	15.49		184.96	8.57	
Current Tax Expense Relating to Prior Years	-	-		38.63	-	
Net Profit	**1,579.25**	**1,146.57**	**37.74%**	**2,682.01**	**1,091.01**	**146%**
Net Profit Margin (%)	**27.29%**	**24.06%**	**323 BPS**	**24.01%**	**18.03%**	**598 BPS**
EPS (Diluted)	8.71	8.14	7.00%	16.65	9.70	**72%**

Balance sheet (Standalone)

Anondita Medicare Limited
(Formerly known as Anondita Healthcare)

(Subsidiary, Anondita Pharma and Latex Limited (Formerly Known as M/s Anondita Healthcare and Rubber Products India Limited., w.e.f. 01/04/2024)

Figures In ₹ Lakhs, Margin In %, EPS in ₹

Equities and Liabilities	FY26	FY25
Shareholder's Funds		
Share Capital	1,808.66	1,329.36
Reserves & Surplus	9,494.38	1,430.41
Minority Interest		
Total	**11,303.04**	**2,759.77**
Non-Current Liabilities		
Long Term Borrowings	2,359.62	1,190.76
Other Long term Liability		
Long Term Provisions	17.8	9.83
Deferred Tax Liability	193.52	8.56
Total Non-Current Liabilities	**2,570.94**	**1,209.15**
Current Liabilities		
Short Term Borrowings	967.8	1,548.34
Trade Payables		
Total oustanding dues of Micro enterprises & small enterprises	141.23	99.37
Total outstanding dues of creditors	652.64	253.21
Other current liabilities	193.85	134.74
Short Term Provisions	463.62	320.06
Total Current Liabilities	**2,419.14**	**2,355.72**
Total	**16,293.12**	**6,324.64**

Assets	FY26	FY25
Non-current Assets		
Fixed Assets	3,907.98	1,235.16
Goodwill		
Capital work-in-progress	4,149.50	649.61
Non-current investments	351.58	351.58
Deferred Tax Assets (Net)		
Long Term Loans & Advances	220.79	37.66
Other Non Current Assets	0.16	0.24
Total Non-current Assets	**8,630.01**	**2,274.25**
Current Assets		
Inventories	1,349.14	896.28
Trade Receivables	3798.80	1660.42
Cash & Cash Equivalents	954.10	35.56
Short Term Loans & Advances	1109.75	1150.00
Other Current Assets	451.32	308.13
Total Current Assets	**7,663.11**	**4,050.39**
Total	**16,293.12**	**6,324.64**

SWOT Analysis

Strengths

Established condom manufacturer in India with **own brand and manufacturing facility.**

Strong demand driven by rising **STD awareness** and preventive healthcare adoption.


Well-recognized presence in North India with a diversified product portfolio.

Fully integrated in-house printing, packaging, and boxing—lower costs, minimal vendor dependency.

CNG biofuel operations—cost-efficient and environmentally superior to competitors.

Threats

Fluctuating latex prices, which may impact input costs and margins.



Weaknesses

Dependence on **latex raw material supply,** exposing the business to procurement and price volatility.

Advantage as one of the few manufacturers using **environmentally friendly fuels.**

Potential market opportunities arising from **industry consolidation,** including HLL Lifecare's divestment.

Opportunities

Growing shift toward **sustainable and eco-friendly manufacturing.**



THANK YOU

Anondita Medicare Limited

Flat No.704 Narmada Block, N6, Sec-D, Pkt-6 Vasant Kunj,
New Delhi, India110070.

Telephone No.: +91 7678182056

Website: www.anonditamedicare.com

Email id: info@anonditamedicare.com

Orim Connect
Investor Relations Partner

Phone: +91 82085 63201

Email: letsconnect@orim.in

Website: www.orim.in/orim-connect/